CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease

IDrugs

Volumn 12, Issue 4, 2009, Pages 243-251

  Solaro, R J ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CARDIAC MYOSIN; CK 1827452; CYCLIC AMP; INOTROPIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; CALCIUM TRANSPORT; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEART FAILURE; HEART FUNCTION; HUMAN; NONHUMAN; REVIEW; SARCOMERE; STRUCTURE ACTIVITY RELATION;

ACUTE DISEASE; CARDIOTONIC AGENTS; CHRONIC DISEASE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEART FAILURE; HUMANS; MYOCARDIUM; MYOSINS; SARCOMERES; TREATMENT OUTCOME;

EID: 64349116900     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Effects of acidosis and hypoxia on the response of isolated ferret cardiac muscle to inotropic agents. Than N, Shah N, White J, Lee JA, Orchard CH CARDIOVASC RES 1994 28 8 1209-1217
2. The cardiac myosin activator, CK1122534, increases contractility in adult cardiac myocytes but does not affect the calcium transient or depend on second messenger signaling. Niu C, Anderson RL, Cox DR, Morgan BP, Morgans DJ, Malik F, Elias KA CIRCULATION 2004 110 17 Abs 2256
3. Cytokinetics presents data on CK-1827452 at the 2005 Annual Heart Failure Society of America meeting: Non-clinical research findings support advancement of drug candidate. Cytokinetics Inc PRESS RELEASE 2005 September 19
4. Cytokinetics announces selection of CK-1827452 as development candidate for chronic heart failure. Cytokinetics Inc PRESS RELEASE 2005 December 07
5. Cytokinetics announces presentation of phase I clinical trial data for CK-1827452 during recent and late breaking trials session at the 2006 Heart Failure Society of America annual meeting. Cytokinetics Inc PRESS RELEASE 2006 September 13
6. The selective cardiac myosin activator, CK-1827452, a calcium-independent inotrope, increases left ventricular systolic function by increasing ejection time rather than the velocity of contraction. Malik F, Teerlink JR, Escandon RD, Clarke CP, Wolff AA CIRCULATION 2006 114 18 Suppl Abs 2169
7. Activating cardiac myosin, a novel inotropic mechanism to improve cardiac function in conscious dogs with congestive heart failure. Shen Y, Vatner SF, Morgans DJ, Malik F CIRCULATION 2006 114 18 Suppl Abs 1439
8. Cytokinetics begins intravenous CK-1827452 phase IIa trial of for cardiac failure. Cytokinetics Inc PRESS RELEASE 2007 April 12
9. Cytokinetics, Incorporated reports second quarter 2007 financial results: Company provides update on cardiovascular and oncology clinical programs. Cytokinetics Inc PRESS RELEASE 2007 July 31
10. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure. Wehrens XHT CURR OPIN INVEST DRUGS 2007 8 9 769-777
11. The cardiac myosin activator CK-1316719 increases myofibril ATPase activity and myocyte contractility in a rat model of heart failure. Anderson RL, Kawas RF, Pokrovskii MV, Godinez G, Lee KL, Mak J, Morgan BP, Morgans DJ, Malik F, Sakowricz R, Elias KA CIRCULATION 2006 114 18 Suppl PG 276
12. The cardiac myosin activator, CK1122534, increases contractility in adult cardiac myocytes without altering the calcium transient. Niu C, Anderson RL, Cox DR, Qian X, Morgan BP, Malik F, Morgans DJ, Elias KA MOL BIOL CELL 2004 15 Suppl S 271A
13. The cardiac myosin activator, CK-1122534, overcomes the myosin II inhibitors 2,3-butanedione-2-monoxime and (-)-S-blebbistatin without affecting the Ca2+ transient in ventricular myocytes. Anderson RL, Niu C, Elias KA MOL BIOL CELL 2004 15 Suppl S 271A
14. Activation of cardiac sarcomere ATPase by CK-1122534, a small molecule agent that specifically targets cardiac myosin. Rodriguez HM, Sylvester S, Qian X, Morgan BP, Morgans DJ, Malik F, Sakowicz R MOL BIOL CELL 2004 15 Suppl S 32A
15. Cardiac myosin activator CK-1316719 increases myocyte contractility and myosin ATPase activation in a model of heart failure. Anderson R, Kawas R, Pokrovskii M, Godinez G, Lee K, Mak J, Morgan B, Morgans D, Malik F, Sakowicz R, Elias K CIRC RES 2006 114 18 Suppl PG 276
16. The cardiac myosin activator, CK-1827452, accelerates the enzymatic step gating entry of myosin into its force generating state. Rodriguez HM, Kawas R, Hartman JJ, Malik F, Sakowicz R BIOPHYS J 2007 Suppl S 481A · Presents in vitro data demonstrating that CK-1827452 had an inhibitory effect on myosin-free inorganic phosphate release in the absence of actin and a stimulatory effect in the presence of actin. These results suggested that CK-1827452 increased entry of the myosin cross-bridges into the force-generating state, indicating a prolongation of the duty cycle.
17. Cytokinetics starts phase IIa cardiac disease trial of CK-1827452. Cytokinetics Inc PRESS RELEASE 2008 April 29
18. Cytokinetics provides updates from phase I clinical trials of CK-1827452. Cytokinetics Inc PRESS RELEASE 2008 June 13
19. The selective cardiac myosin activator, CK-1827452, increases systolic function in heart failure. Cleland JGF, FI Malik J CARD FAIL 2008 14 6 Suppl 1 Abs 210
20. Rationale and design for a phase II study evaluating the effect of the cardiac myosin activator, CK-1827452, on cardiac function, hemodynamics, and myocardial oxygen consumption in patients with heart failure. Parker JD, Michaels AD, Kass DA, Wolff AA, Felker GM, Malik FI J CARD FAIL 2008 14 6 Suppl 1 S79
21. Cytokinetics announces phase IIa clinical trial results relating to CK-1827452 in patients with ischemic cardiomyopathy and angina. Cytokinetics Inc PRESS RELEASE 2008 December 18
22. The selective cardiac myosin activator, CK-1827452, increases systolic function in a concentration-dependent manner in patients with stable heart failure (10/8/08). Cleland JGF, Nifontov EM, McMurray JJV, Senior R, Lang CC, Clarke CP, Francis D, Greenberg B, Mayer J, Monaghan M, Neyses L et al J CARD FAIL 2008 14 9 797-798 ·· Presents data from a phase IIa, multicenter, double-blind, randomized, placebo-controlled clinical trial with escalating doses of CK-1827452 in patients with stable heart failure (n = 40). At CK-1827452 plasma concentrations > 100 ng/ml, statistically significant placebo-corrected increases from baseline were observed in systolic ejection time (24 to 98 ms; p < 0.0001) and fractional shortening (2 to 4%; p < 0.05). Statistically significant placebo-corrected increases from baseline were observed in stroke volume (6 to 14 ml; p < 0.01) at CK-1827452 plasma concentrations > 200 ng/ml.
23. Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Solaro RJ, Ruegg JC CIRC RES 1982 51 3 290-294
24. Mechanisms and use of calcium-sensitizing agents in the failing heart. Kass DA, Solaro RJ CIRCULATION 2006 113 2 305-315
25. A dominant role of cardiac molecular motors in the intrinsic regulation of ventricular ejection and relaxation. Hinken AC, Solaro RJ PHYSIOL 2007 22 73-80
26. Calcium, thin filaments, and the integrative biology of cardiac contractility. Kobayashi T, Solaro RJ ANNU REV PHYSIOL 2005 67 39-67
27. Multiplex kinase signaling modifies cardiac function at the level of sarcomeric proteins. Solaro RJ J BIOL CHEM 2008 283 40 26829-26833
28. The contractile apparatus as a target for drugs against heart failure: Interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Sorsa T, Pollesello P, Solaro RJ MOL CELL BIOCHEM 2004 266 1-2 87-107
29. Ablation of ventricular myosin regulatory light chain phosphorylation in mice causes cardiac dysfunction in situ and affects neighboring myofilament protein phosphorylation. Scruggs SB, Hinken AC, Thawornkaiwong A, Robbins J, Walker LA, de Tombe PP, Geenen DL, Buttrick PM, Solaro RJ J BIOL CHEM 2009 284 8 5097-5106
30. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ, Potter JD, Knollmann BC J CLIN INVEST 2008 118 12 3893-3903
31. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, Lu QW, Wang YY, Zhan DY, Mochizuki M, Kita S et al CIRC RES 2007 101 2 185-194
32. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX J AM COLL CARDIOL 2004 43 12 2177-2182
33. In vitro and in vivo characterization of CK-1827452, a selective cardiac myosin activator. Anderson RL, Sueoka SH, Lee KH, Rodriguez HM, Kawas RF, Godinez G, Morgan BP, Sakowicz R, Morgans DJ, Malik F, Elias KA J CARD FAIL 2006 12 6 S86 ·· Presents important in vitro data demonstrating that CK-1827452 did not affect diastolic length or diastolic Ca2+ levels of field-stimulated rat ventricular myocytes.
34. First clinical trial of the selective cardiac myosin activator, CK-1827452, in heart failure: Effect of dose and plasma concentration on systolic function. Cleland JGF, Nifontov EM, Mc Murray JJV, Senior R, Lang CC, Clarke CP, Francis D, Greenberg B, Mayet J, Monaghan M, Neyses L et al EUR HEART J SUPPL 2008 29 Abs 299
35. 2 in heart failure with left ventricular hypertrophy. Shen Y, Zhang Y, Morgans DJ, Vatner SF, Malik F ACC 2008 51 10 Suppl Abs 1016-4
36. Oral bioavailability of the selective cardiac myosin activator CK-1827452: Chronic oral inotropic therapy for heart failure? Jerling M, Chew T, Escandon R, Lee J, Saikali K, Venables E, Clarke C, Malik F, Wolff A J CARD FAIL 2007 13 6 S148
37. Systolic ejection time is a sensitive indicator of left ventricular systolic function during treatment with the selective cardiac myosin activator, CK-1827452. Malik FI, Saikali KG, Clarke CP, Teerlink JR, Wolff AA J CARD FAIL 2007 13 6 S145-S146
38. The selective cardiac myosin activator, CK-1827452, increases left ventricular systolic function by increasing ejection time: Results of a first-in-human study of a unique and novel mechanism. Teerlink JR, Malik FI, Clarke CP, Saikali KG, Escandon RD, Lee JH, Wolff AA J CARD FAIL 2006 12 9 763 ·· Presents data from a phase I, first-in-human, double-blind, randomized, placebo-controlled, dose-escalation clinical trial of CK-1827452 (0.005 to 1.0 mg/kg/h, 6 h iv infusion once weekly for 4 weeks) administered to healthy male volunteers (n = 34). CK-1827452 treatment was associated with linear dose-dependent increases in left ventricular systolic ejection fraction and fractional shortening. CK-1827452 was generally well tolerated, with an MTD determined of 0.5 mg/kg/h, at which the mean systolic blood pressure decreased by 13 mmHg (p < 0.0001) and 7.4 mmHg (p < 0.05) in standing and supine volunteers, respectively.
39. Direct activation of cardiac myosin, a novel mechanism for improving cardiac function. Malik F, Shen Y, Katori T, Sueoka SH, Anderson R, Cox D, Garard M, Hartman J, Kim S, Kraynack E, Kuklov A et al CIRC RES 2005 97 2 Abs 136
40. The cardiac myosin activator CK-1827452-induced myocyte contractility is unchanged in the presence of β-blockade. Anderson RL, Pokrovskii M, Suekawa K, Rodriguez HM, Elias KA AM SOC CELL BIOL 2007 47 Abs 669
41. In vitro and in vivo efficacy of the cardiac myosin activator CK-1827452. Anderson RL, Sueoka SH, Rodriguez HM, Lee KH, Cox DR, Kawas R, Morgan BP, Sakowicz R, Morgans Jr DJ, Malik F, Elias KA AM SOC CELL BIOL 2005 45 Abs 1728
42. Cellular responses of the myosin activator CK-0689705 in normal and heart failure models. Niu C, Cox D, Lee K, Sylvester S, Sueoka S, Qian X, Feng B, Malik F, Morgans Jr D, Hartman J, Sakowicz R et al AM SOC CELL BIOL 2004 44 Abs 1501
43. Effects of cardiac myosin activators on excitation-contraction (E-C) coupling in ventricular myocytes. Anderson R, Pokrovskii M, Elias K BIOPHYS J 2007 Suppl S 133A
44. Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. Malik F, Elias KA, Finer JT, Morgan BP, Sakowicz R, Anderson R, Baliga R, Conn L, Cox D, Garard M, Hartman J et al J CARD FAIL 2005 11 6 Suppl 1 Abs 017 · Presents in vitro data from field-stimulated rat ventricular myocytes. CK-1827452 did not affect the peak amplitude or dynamics of the Ca2+ transient, but increased the extent of myocyte shortening. Furthermore, CK-1827452 had no effect on PDE3 activity and was unaffected by concurrent β-blockers. In vivo data from dog models of heart failure suggested increased fractional shortening, cardiac output and stroke volume, with no apparent effects on diastolic function or on waste of oxygen consumption, indicating an increased cardiac contractile function.
45. Heart failure: How big is the problem? Who are the patients? What does the future hold? Ansari M, Massie BM AM HEART J 2003 146 1 1-4
46. Advanced heart failure: A call to action. Russell SD, Miller LW, Pagani FD CONGEST HEART FAIL 2008 14 6 316-321
47. Integration of cardiac myofilament activity and regulation with pathways signaling hypertrophy and failure. de Tombe PP, Solaro RJ ANN BIOMED ENG 2000 28 8 991-1001
48. Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Loeb HS, Bredakis J, Gunner RM CIRCULATION 1977 55 2 375-378
49. Amrinone: A new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. LeJemtel TH, Keung E, Sonnenblick EH, Ribner HS, Matsumoto M, Davis R, Schwartz W, Alousi AA, Davolos D CIRCULATION 1979 59 6 1098-1104
50. Comparison of β blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Fauchier L, Grimard C, Pierre B, Nonin E, Gorin L, Rauzy B, Cosnay P, Babuty D, Charbonnier B AM J CARDIOL 2009 103 2 248-254
51. How molecular motors work. Spudich JA NATURE 1994 372 6506 515-518
52. A detailed kinetic analysis of the cardiac myosin activator, CK-1213296, suggests it improves cardiac contractility by accelerating transition from the weak to strongly bound states. Rodriguez HM, Sylvester S, Hartman J, Shen YT, Kass DA, Vatner SF, Malik F, Sakowicz R KEYSTONE SYMP - MOL MECH CARDIAC DIS REGENER 2006 Abs 129
53. Cytokinetics, Incorporated reports fourth quarter and year end 2008 financial results. Cytokinetics Inc PRESS RELEASE 2009 February 10
54. Cardiovascular program: CK-1827452. Cytokinetics Inc COMPANY WORLD WIDE WEB SITE 2009 February 18
55. p38-MAPK induced dephosphorylation of α-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Vahebi S, Ota A, Li M, Warren CM, de Tombe PP, Wang Y, Solaro RJ CIRC RES 2007 100 3 408-415
56. Cardiac Ca2+ signaling and Ca2+ sensitizers. Endoh M CIRCULATION J 2008 72 12 1915-1925
57. CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Wolska BM, Kitada Y, Palmiter KA, Westfall MV, Johnson MD, Solaro RJ AM J PHYSIOL 1996 270 1 Pt 2 H24-H32
58. Reversal of effects of acidosis on contraction of rat heart myocytes by CGP-48506. Minami H, Wolska BM, Stojanovic MO, Solaro RJ FRONT BIOSCI 2008 13 5638-5645
59. Ca2+ sensitizer Org-30029 reverses acidosis- and BDM-induced contractile depression in canine myocardium. Watanabe A, Tomoike H, Endoh M AM J PHYSIOL 1996 271 5 Pt 2 H1829-H1839